Pertussis vaccination in newborns
Expert Review of Vaccines, ISSN: 1476-0584, Vol: 8, Issue: 2, Page: 153-157
2009
- 16Citations
- 25Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations16
- Citation Indexes15
- 15
- CrossRef12
- Clinical Citations1
- PubMed Guidelines1
- Captures25
- Readers25
- 25
Article Description
Bordetella pertussis remains in fifth place among the leading etiologies of vaccine-preventable deaths in children around the world. The impact of this disease is considerable in North America, Latin America, Europe and other parts of the world. Therefore, new vaccination strategies have been recommended in the last decade, predominantly to protect infants younger than 2 months of age, which is the most vulnerable age group and, thus, at greater risk of hospitalizations, complications and death. These new strategies include vaccination with the tetanus, diphtheria and pertussis vaccine in adolescents, adults and postpartum women ('cocoon strategy'); while vaccination of pregnant women is still controversial. Although recent clinical trials have shown the potential benefits of vaccinating newborns with monovalent or combined acellular pertussis vaccines, no vaccine is yet approved for this age group. The paper under evaluation describes the results of a prospective clinical trial in which neonatal immunization with an acellular pertussis vaccine was administered between 2 and 5 days of age. The vaccine was shown to be safe, well tolerated and immunogenic; however, decreased antibody responses were seen, predominantly to Haemophilus influenzae type b. © 2009 Expert Reviews Ltd.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know